(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Friday said their drug conjugate Enhertu has been approved for patients in the US with unresectable or metastatic non-small cell lung cancer. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said results from a trial showed promising clinical activity in patients with non-small cell lung cancer. Read More
(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said their drug conjugate Enhertu has been approved for more patients in the US. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Says new tablet formulation of Calquence, whose generic name is acalabrutinib, has been approved in the US for all current indications. These include adult patients with chronic lymphocytic leukaemia, the most prevalent type of leukaemia in adults, and with blood cancer small lymphocytic lymphoma; and for patients with relapsed or refractory mantle cell lymphoma, an uncommon subtype of B-cell non-Hodgkin lymphoma. AstraZeneca says the approval by the US Food & Drug Administration was based on the Elevate-Plus trials, conducted in 116 healthy subjects. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday: Read More
(Alliance News) - AstraZeneca PLC said on Thursday that Lynparza, which was co-developed with Merck & Co Inc, has received approval in the EU for early high-risk breast cancer, triggering a milestone payment from its collaborator. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday: Read More
(Alliance News) - Stock prices in London were higher on Friday with deteriorating economies prompting expectations for interest rate hikes to be scaled back, as an action-packed week of company and economic news draws to a close. Read More
(Alliance News) - Stock prices in London opened higher on Friday amid hopes the US Federal Reserve will pump the brakes on aggressive rate hikes, while banks boosted the FTSE 100 with the sector awash in cash. Read More
(Alliance News) - AstraZeneca PLC on Friday said it delivered a strong first-half, boosted by demand for its cancer treatments, and lifted its full-year revenue guidance. Read More
(Alliance News) - AstraZeneca on Friday said it delivered a strong first-half boosted by demand for its cancer treatments. Read More
(Alliance News) - Stock prices in London are seen opening higher on Friday on speculation that the Federal Reserve will slow its pace of interest rate hikes after the US economy contracted for two straight quarters. Read More
(Alliance News) - European equities were higher at midday on Monday, bouncing back from a lower start, as investors took a warning from a business poll that showed Germany is on "brink of recession" in their stride. Read More
(Alliance News) - AstraZeneca PLC on Monday said it won two recommendations for approval in the EU and one priority review in the US. Read More
(Alliance News) - A UK government led by Rishi Sunak will be good news for pharmaceutical firms, while Liz Truss could lift retail share prices with her plan to cut personal income taxes, analysts at Brewin Dolphin said on Thursday, after the race to Number 10 was whittled down to two. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said a breast cancer drug developed with Tokyo-based partner Daiichi Sankyo Co Ltd has been approved in the European Union. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC's savolitinib in combination with Astra's osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning: Read More